CatchMe Therapeutics

CatchMe Therapeutics Pioneering the Future of RNA Therapeutics At CatchMe, we are driven by a bold vision: to unlock the untapped potential of RNA-binding proteins (RBPs) for transformative therapies. Our mission is to go beyond conventional approaches, targeting RBPs that have been largely overlooked to address critical unmet needs in cancer and beyond. At the heart of our innovation is SAPIR—our proprietary technology platform. SAPIR stands for Smart Active Pharmaceutical Ingredient RNA, encapsulating our approach to designing and delivering RNA-based therapies that are smarter, more precise, and highly effective. Beyond its scientific meaning, SAPIR also holds symbolic significance: in Hebrew, “Sapir” means sapphire, a precious gemstone that represents clarity, strength, and value—qualities we strive to reflect in our transformative therapies. Our lead program focuses on oligonucleotide-based therapies for Triple-Negative Breast Cancer (TNBC), a highly aggressive and underserved disease. With SAPIR and a pipeline built on cutting-edge science, CatchMe is uniquely positioned to advance precision medicine solutions that deliver meaningful impact for patients. We are powered by a passionate team of scientists, innovators, and industry experts united by a shared commitment to revolutionizing RNA-based treatments. Whether it’s advancing new discoveries or tackling the complexities of CMC development, our focus remains on building a pipeline that drives rapid, impactful clinical translation. At CatchMe, we believe in collaboration, innovation, and the urgency to create life-changing therapies. Join us as we lead the charge in RNA therapeutic innovation and transform the future of medicine, one discovery at a time. #RNAtherapeutics #SAPIR #PrecisionMedicine #BiotechInnovation